NASDAQ:ARDS

Aridis Pharmaceuticals - ARDS Stock Forecast, Price & News

$0.93

+0.03 (+3.33%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.89
▼
$0.95
50-Day Range: $0.73
▼
$2.47
52-Week Range: $0.68
▼
$4.34

Volume: 125,605 shs
Average Volume: 285,264 shs
Market Capitalization: $16.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Aridis Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 975.3% Upside
$10.00 Price Target
Short Interest: Healthy
0.71% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.20
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.23) to ($0.53) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

836th out of 1,093 stocks

Pharmaceutical Preparations Industry

407th out of 547 stocks

3.3

Analyst's Opinion

Consensus Rating
Aridis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Aridis Pharmaceuticals has a forecasted upside of 975.3% from its current price of $0.93.
Amount of Analyst Coverage
Aridis Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.71% of the outstanding shares of Aridis Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Aridis Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aridis Pharmaceuticals has recently increased by 42.19%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aridis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Aridis Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARDS.

3.4

News and Social Media Coverage

News Sentiment
Aridis Pharmaceuticals has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Aridis Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
12 people have searched for ARDS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aridis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aridis Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.90% of the stock of Aridis Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.50% of the stock of Aridis Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aridis Pharmaceuticals are expected to decrease in the coming year, from ($0.23) to ($0.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aridis Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aridis Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Aridis Pharmaceuticals (NASDAQ:ARDS) Stock

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Stock News Headlines

October 2, 2022 | americanbankingnews.com

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Short Interest Up 42.2% in September

September 26, 2022 | finance.yahoo.com

Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock

September 21, 2022 | finance.yahoo.com

Wave Therapeutics (WVE) Up on Update From Huntington's Study

September 20, 2022 | seekingalpha.com

ARDS Aridis Pharmaceuticals, Inc.

September 19, 2022 | finance.yahoo.com

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

September 19, 2022 | finance.yahoo.com

Intellia (NTLA) Reports Positive Results for CRISPR Candidates

September 16, 2022 | uk.finance.yahoo.com

Aridis Pharmaceuticals, Inc. (ARDS)

August 17, 2022 | seekingalpha.com

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

August 16, 2022 | finance.yahoo.com

Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates

August 16, 2022 | finance.yahoo.com

Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update

August 10, 2022 | finance.yahoo.com

Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action

August 10, 2022 | finance.yahoo.com

Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates

July 1, 2022 | nasdaq.com

Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing

July 1, 2022 | apnews.com

RedChip Interviews Aridis Pharmaceuticals’ CEO Vu Truong

June 30, 2022 | finance.yahoo.com

RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong

June 3, 2022 | finance.yahoo.com

Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7

May 16, 2022 | finance.yahoo.com

Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates

May 16, 2022 | finance.yahoo.com

Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update

February 17, 2022 | finance.yahoo.com

Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study

February 17, 2022 | seekingalpha.com

Aridis stock rises 6% as antibody cocktail AR-701 protects against Omicron in animal models

February 17, 2022 | nasdaq.com

Why Aridis Pharma Is Rising In Pre-market?

February 17, 2022 | finance.yahoo.com

Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

January 31, 2022 | seekingalpha.com

Wolfspeed, Galapagos, BlackBerry among premarket losers' pack

January 28, 2022 | benzinga.com

How Is The Market Feeling About Aridis Pharmaceuticals Inc?

January 27, 2022 | msn.com

Peering Into Aridis Pharmaceuticals Inc's Recent Short Interest

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Company Calendar

Last Earnings: 8/16/2022
Today: 10/01/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARDS
CUSIP: N/A
CIK: 1614067
Web: www.aridispharma.com
Phone: (408) 385-1742
Fax: 408-960-3822
Employees: 33
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +975.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,190,000.00
Net Margins: -1,954.56%
Pretax Margin: -1,776.79%
Return on Equity: N/A
Return on Assets: -214.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.41
Quick Ratio: 0.41

Sales & Book Value

Annual Sales: $1.53 million
Price / Sales: 10.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.93) per share
Price / Book: -1.00

Miscellaneous

Outstanding Shares: 17,700,000
Free Float: 15,418,000
Market Cap: $16.46 million
Optionable: Not Optionable
Beta: 1.25

Key Executives

Dr. Vu L. Truong Ph.D. (Age 58)
Founder, CEO, Chief Scientific Officer & Director
Comp: $576.25k

Mr. Fred Kurland J.D. (Age 71)
M.B.A., Chief Financial Officer
Comp: $305.89k

Dr. Hasan Jafri M.D.
Chief Medical Officer

Mr. Jeffrey J. Fessler Esq. (Age 59)
J.D., Acting Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

Commonwealth Equity Services LLC
Sold 10,000 shares on 7/19/2022
Ownership: 3.205%

View All Insider Transactions
View All Institutional Transactions

ARDS Stock - Frequently Asked Questions

Should I buy or sell Aridis Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDS shares.
View ARDS analyst ratings or view top-rated stocks.
What is Aridis Pharmaceuticals' stock price forecast for 2022?: 2 brokerages have issued 12 month target prices for Aridis Pharmaceuticals' stock. Their ARDS share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 975.3% from the stock's current price.
View analysts price targets for ARDS or view top-rated stocks among Wall Street analysts.
How have ARDS shares performed in 2022?: Aridis Pharmaceuticals' stock was trading at $2.33 on January 1st, 2022. Since then, ARDS shares have decreased by 60.1% and is now trading at $0.93.
View the best growth stocks for 2022 here.
When is Aridis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ARDS earnings forecast.
How were Aridis Pharmaceuticals' earnings last quarter?: Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) issued its quarterly earnings data on Tuesday, August, 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.39.

What other stocks do shareholders of Aridis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX).
When did Aridis Pharmaceuticals IPO?: (ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.
What is Aridis Pharmaceuticals' stock symbol?: Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."
How do I buy shares of Aridis Pharmaceuticals?: Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aridis Pharmaceuticals' stock price today?: One share of ARDS stock can currently be purchased for approximately $0.93.
How much money does Aridis Pharmaceuticals make?: Aridis Pharmaceuticals (NASDAQ:ARDS) has a market capitalization of $16.46 million and generates $1.53 million in revenue each year. The company earns $-42,190,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.
How can I contact Aridis Pharmaceuticals?: Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The official website for the company is www.aridispharma.com. The company can be reached via phone at (408) 385-1742, via email at jwong@bplifescience.com, or via fax at 408-960-3822.

This page (NASDAQ:ARDS) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aridis Pharmaceuticals - ARDS Stock Forecast, Price & News

Aridis Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows